First-round funding for eye technology firm HyperBranch
This article was originally published in Clinica
HyperBranch Medical Technology, a Raleigh, North Carolina-based developer of eye surgery products, has raised $6m in a first round of venture capital financing. The funds, contributed by The Aurora Funds (Durham, North Carolina) and HIG Ventures (Miami, Florida), will help the company carry out preclinical and clinical development of its two lead products, a synthetic lens for use in cataract surgery and wound-sealing glue for use in ophthalmics.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.